efficacy of hepatitis b vaccine in those who lost hepatitis b surface antigen during follow-up

Efficacy of Hepatitis B vaccine in those who lost Hepatitis B surface antigen during follow-up

BACKGROUND The level of HBsAg in some chronic hepatitis B virus (HBV)-infected individuals may decline over time so that it is not detectable in serum. OBJECTIVE To assess the efficacy of HBV vaccine in those who lost their HBsAg without seroconverssion to anti-HBs antibody. PATIENTS AND METHODS From April 1993 to December 2008, of 1603 chronic HBV-infected individuals, 34 (22 men and 12 wo...

broader use of hepatitis b virus vaccine: efficacy in those who lost hepatitis b surface antigen during follow-up

Broader use of hepatitis B virus vaccine: Efficacy in those who lost hepatitis B surface antigen during follow-up

The article “efficacy of hepatitis B vaccine in those who lost hepatitis B surface antigen during follow-up” published recently in Hepatitis Monthly (1), described the efficacy of HBV vaccine in chronic HBV patients who had been found negative for HBsAg and HBV DNA in sera. The manuscript was highlighted by an Editorial in the same issue (2). The manuscript dealt with a group of chronic HBV pat...

immune response to hepatitis b vaccine in patients who lost hepatitis b surface antigen during follow up

Immune response to hepatitis B vaccine in patients who lost hepatitis B surface antigen during follow up

We read with interest the article by Taheri et al. regarding the efficacy of Hepatitis B vaccine in those who lost Hepatitis B surface antigen (HbsAg) during follow up (1). As the authors mentioned, a protective anti-HBs level developed in 24% of chronic HBsAg-positive subjects who had already lost their HBsAg after hepatitis B vaccination, and the remaining cases need to be monitored for occul...

Surface protein mutations in chronic hepatitis B patients who received hepatitis B vaccine therapy

Objective (s):The aim of this study was to determine the correlation between vaccine therapy and appearance of mutations in hepatitis B surface antigen (HBsAg)-positive chronic hepatitis B virus (HBV) patients. Materials and Methods: 16 patients received the HBV vaccine and another 16 individuals from the control group did not. The surface gene was amplified and directly sequenced from samples...